Karyopharm Therapeutics KPTI 深 沪
等待开盘 09-23 09:30:00 美东时间
5.85
+0.440
+8.13%
华盛通- 最 高5.9188
- 今 开5.49
- 成交量 14.96万股
- 最 低 5.32
- 昨 收 5.41
- 总市值 5072.71万
- 52周最高 16.95
- 市盈率 静 --
- 换手率 1.73%
- 52周最低 3.51
- 委 比 33.33%
- 总股本 867.13万
- 历史最高 735.075
- 量 比 1.93
- 振 幅 11.07%
- 历史最低 5.32
- 每 手 1
- 风险率 0.23%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Karyopharm Completes Enrollment In Phase 3 Trial Testing New Combo Therapy For Myelofibrosis Patients
Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has completed enrollment in the Phase 3 SENTRY trial, which is evaluating
09-10 19:02
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass., Sept. 2, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that th...
09-03 04:05
Baird Maintains Outperform on Karyopharm Therapeutics, Lowers Price Target to $25
Baird analyst Michael Ulz maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Outperform and lowers the price target from $42 to $25.
08-12 19:41
Karyopharm Therapeutics Affirms FY2025 Sales Guidance of $140M-$155M vs $145.358M Est
2025 Financial OutlookBased on its current operating plans, Karyopharm expects the following for full year 2025:Total revenue to be in the range of $140 million to $155 million. Total revenue consists of U.S. XPOVIO net
08-11 19:34
Earnings Scheduled For August 11, 2025
Companies Reporting Before The Bell • Niu Techs (NASDAQ:NIU) is expected to rep...
08-11 16:32
Earnings Outlook For Karyopharm Therapeutics
Karyopharm Therapeutics (NASDAQ:KPTI) is set to give its latest quarterly earni...
08-09 04:06
制药巨头扎堆做“减法”：20家药企7月宣布裁员
2025 年已经过半，裁员、削减成本，成为众多药企不得不面对的现实。据 Fierce Biotech 统计，仅在今年 7 月，就有 20 家药企宣布了裁员计划...
08-01 12:49
Karyopharm Therapeutics Explores Financing and Strategic Options
Karyopharm Therapeutics ( ($KPTI) ) has issued an update. Karyopharm Therapeuti...
07-11 19:47
HC Wainwright & Co. Assumes Karyopharm Therapeutics at Buy, Announces Price Target of $27
HC Wainwright & Co. analyst Robert Burns assumes Karyopharm Therapeutics (NASDAQ:KPTI) with a Buy rating and announces Price Target of $27.
07-11 18:15
Karat Packaging Inc. Announces Pricing of Secondary Offering of Common Stock
Karat Packaging Inc. announced the pricing of an underwritten secondary offering of 1.5 million shares of its common stock by certain management team members at $27.00 per share. Underwriters have a 30-day option to purchase an additional 225,000 shares. The offering is expected to close on June 12, 2025. The Company will not receive proceeds from the sale. BofA Securities and William Blair & Company are acting as joint lead book-runners. The off...
06-11 02:15
